title: [A case report of combined hepatocellular-cholangiocarcinoma whose lymph node recurrence effectively treated with UFT].
abstract: Primary liver cancer with lymph node metastasis was recognized as poor prognosis. We herein report a case of post operative lymph node recurrence treated with UFT. A 74-year-old man with a huge mass lesion in the right liver with para Aortic lymph node metastasis admitted our hospital in April 2007. Extended right lobe hepatectomy and lymph node dissection were performed in May. A histological examination of the resected specimen showed a combined hepatocellular-cholangiocarcinoma with three lymph node metastasis. Computed tomography(CT)revealed intra hepatic metastasis (S3) and right adrenal grand metastasis 5 months after surgery. Transarterial embolization (TAE) and right adrenalectomy were performed for each metastasis. CT revealed a lymph node metastasis at the right side of infra vena cava 1 year after surgery. He was treated by oral administration of UFT (200 mg/day). The AFP and PIVKA-II value gradually decreased after administration of UFT. The size of lymph node metastasis became small confirmed by CT. But the AFP and PIVKA-II value increased 1 year and 7 months after surgery. TAE was performed against lymph node metastasis 1 year and 9 months after surgery. This case suggests UFT is useful for suppressing the growth of the lymph node metastasis.
authors.affiliation: Department of Surgery, Toyonaka Municipal Hospital.
authors.forename: Junzo
authors.initials: J
authors.lastname: Shimizu
authors.forename: Shoho
authors.initials: S
authors.lastname: Hayashi
authors.forename: Keizo
authors.initials: K
authors.lastname: Dono
authors.forename: Taku
authors.initials: T
authors.lastname: Yasumoto
authors.forename: Masahiro
authors.initials: M
authors.lastname: Zenitani
authors.forename: Kouji
authors.initials: K
authors.lastname: Munakata
authors.forename: Noriyuki
authors.initials: N
authors.lastname: Watanabe
authors.forename: Kaori
authors.initials: K
authors.lastname: Takamoto
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Kagawa
authors.forename: Taishi
authors.initials: T
authors.lastname: Hata
authors.forename: Kensyu
authors.initials: K
authors.lastname: Kawanishi
authors.forename: Kimimasa
authors.initials: K
authors.lastname: Ikeda
authors.forename: Junya
authors.initials: J
authors.lastname: Fujita
authors.forename: Kenzo
authors.initials: K
authors.lastname: Akagi
authors.forename: Masashi
authors.initials: M
authors.lastname: Kitada
authors.forename: Takashi
authors.initials: T
authors.lastname: Shimano
mesh_terms: D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001650:Bile Duct Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D001653:Bile Ducts, Intrahepatic; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000473:pathology*; D018281:Cholangiocarcinoma / Q000188:drug therapy* / Q000473:pathology*; D003131:Combined Modality Therapy; D004621:Embolization, Therapeutic; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D008207:Lymphatic Metastasis / Q000473:pathology*; D008297:Male; D009364:Neoplasm Recurrence, Local; D005641:Tegafur / Q000008:administration & dosage; D014498:Uracil / Q000008:administration & dosage
chemical_list: D000964:Antimetabolites, Antineoplastic; D005641:Tegafur; D014498:Uracil